Select Language
CD38
CD38 Overview
| English Name | Lymphocyte differentiation antigen CD38 | Approved Drugs | 3 |
| Drugs in Clinical Trials | 48 | Target Synonym | EC:3.2.2.6，EC:2.4.99.20，2-Phospho-Cyclic-ADP-Ribose Transferase，Cyclic ADP-Ribose Hydrolase 1，2-Phospho-ADP-Ribosyl Cyclase，NAD(+) Nucleosidase，CD38 Antigen (P45)，2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase，Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase，ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1，Cluster Of Differentiation 38，CD38 Antigen，EC 2.4.99.20，EC 3.2.2.6，ADPRC1，T10，2'-phospho-ADP-ribosyl cyclase，ADPRC 1，cADPr hydrolase 1，ADP-ribosyl cyclase 1，2'-phospho-cyclic-ADP-ribose transferase，CD38，CD38 Molecule，2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase |
| Highest Development Stage | Approved | ||
| English Name | Lymphocyte differentiation antigen CD38 |
| Target Synonym | EC:3.2.2.6，EC:2.4.99.20，2-Phospho-Cyclic-ADP-Ribose Transferase，Cyclic ADP-Ribose Hydrolase 1，2-Phospho-ADP-Ribosyl Cyclase，NAD(+) Nucleosidase，CD38 Antigen (P45)，2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase，Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase，ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1，Cluster Of Differentiation 38，CD38 Antigen，EC 2.4.99.20，EC 3.2.2.6，ADPRC1，T10，2'-phospho-ADP-ribosyl cyclase，ADPRC 1，cADPr hydrolase 1，ADP-ribosyl cyclase 1，2'-phospho-cyclic-ADP-ribose transferase，CD38，CD38 Molecule，2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 48 |
| Highest Development Stage | Approved |
CD38 Product List
- Product Category
Protein (10)Beads (1)Antibody (1)Kits (1)
- Product Status
Launched (13)
- Species
Human (10)Cynomolgus (1)Mouse (1)Rabbit (1)
- Tag
His Tag (4)His Tag & Avi Tag (1)Fc Tag (2)Mouse IgG Fc Tag (1)- (3)Fc Tag & Avi Tag (1)Avi Tag (1)
- Conjugate
Unconjugated (6)Biotin-labeled (3)- (2)FITC Labeled (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CD8-H5224 |  Human | HEK293 | Human CD38 Protein, His Tag (MALS verified) |  |  |  |
HOT CD8-H5255 | Human | HEK293 | Human CD38 Protein, Fc Tag (MALS verified) |  | | |
HOT CD8-H82E7 | Human | HEK293 | Biotinylated Human CD38 Protein, Avitag™,His Tag (MALS verified) |  | | |
HOT CD8-HF2H5 | Human | HEK293 | FITC-Labeled Human CD38 Protein, His Tag (MALS verified) |  | | |
CD8-H5253 | Human | HEK293 | Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | |
CD8-H8214 | Human | HEK293 | Biotinylated Human CD38 Protein, Avitag™ |  | | |
CD8-H82F5 | Human | HEK293 | Biotinylated Human CD38 Protein, Fc,Avitag™ (MALS verified) |  | | |
CD8-HF255 | Human | HEK293 | FITC-Labeled Human CD38 Protein, Fc Tag |  | | |
CEA-B039 | Human | - | Human Soluble CD38 ELISA Kit | |||
MBC-K010 | Human | - | Human CD38-coupled Magnetic Beads |
Total: 13
- 1
- 2
CD38 Background
CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.
CD38 Synonyms
CD38,T10,cADPr hydrolase 1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mezagitamab | TAK-079 | Phase 3 Clinical | Takeda Pharmaceutical Co Ltd | Autoimmune Diseases; Glomerulonephritis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Nephrosis; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | Details |
| Daratumumab biosimilar (Celltrion) | CT-P44 | Phase 3 Clinical | Celltrion Inc | Multiple Myeloma | Details |
| Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 3 Clinical | SinoCelltech Ltd | Amyloidosis; Autoimmune Diseases; Glomerulonephritis, IGA; Hematologic Neoplasms; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Daratumumab biosimilar (Henlius) | HLX-15 | Phase 3 Clinical | Multiple Myeloma | Details | |
| Recombinant anti-CD38 fully human monoclonal antibody (Henlius Biotech) | Phase 3 Clinical | Amyloidosis; Multiple Myeloma | Details | ||
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 3 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Hematologic Neoplasms; Lupus Erythematosus, Systemic; Multiple Myeloma; Nephrotic Syndrome | Details |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Immunoglobulin Light-chain Amyloidosis; Leukemia, Myeloid, Acute; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Melanoma; Multiple Myeloma; Neoplasms | Details |
| CLL1/CD33/CD38/CD7 CAR-T cell therapy | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Anti-CD38 Monoclonal Antibody (Genrix) | Phase 2 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Multiple Myeloma | Details | |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Autoimmune Diseases; Hematologic Neoplasms; Neuroblastoma | Details |
| REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Antiphospholipid Syndrome; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | Details | |
| CID-103 | TSK011010; CID-103 | Phase 2 Clinical | Tusk Therapeutics Ltd | Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic; Rejection of renal transplantation; Thrombocytopenia | Details |
| BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals, PeptiDream Inc | Multiple Myeloma | Details |
| Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Anemia; Anemia, Aplastic; Blood Platelet Disorders; Glomerulonephritis, IGA; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Lymphoma; Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | Details |
| 89Zr-DFO-daratumumab | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| 64Cu-DOTA-daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Multiple Myeloma | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College) | Phase 1 Clinical | Tongji Medical College | Multiple Myeloma | Details | |
| CD38 CAR T-cells | Phase 1 Clinical | Zhejiang University | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| anti-CD38 CAR T-cell therapy (Shanghai Unicar-Therapy Bio-Medicine Technology/Soochow University/East China Normal University) | Phase 1 Clinical | Soochow University | Leukemia, Myeloid, Acute | Details | |
| actinium-225 labeled daratumumab (Actinium Pharmaceuticals) | Phase 1 Clinical | Actinium Pharmaceuticals Inc, City Of Hope National Medical Center, National Cancer Institute | Hematologic Neoplasms; Multiple Myeloma | Details | |
| T-007 (TNK Therapeutics/Celularity) | Phase 1 Clinical | Tnk Therapeutics Inc | Multiple Myeloma | Details | |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Multiple Myeloma | Details |
| Indium In 111-DOTA-Daratumumab | Phase 1 Clinical | City Of Hope National Medical Center | Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Daratumumab biosimilar (Jushi Biopharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Multiple Myeloma | Details | |
| CD38\CS1 Chimeric Antigen Receptor T Cells therapy(The Second Hospital Of Shandong University) | Phase 1 Clinical | The Second Hospital Of Shandong University | Multiple Myeloma | Details | |
| SAR-444559 | SAR444559; SAR-444559 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| 68Ga-NB-381 | 68Ga-NB381; 68Ga-NB-381; 18F-FDG(The First Affiliated Hospital Of Beijing University) | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Multiple Myeloma | Details |
| Dual CLL1/CD38 targeting CAR-T cell therapy (Gracell Biotechnologies) | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| RB-0021 | RB0021; RB-0021 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma | Details |
| KJ-C2320 | KJ-C2320 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Myeloid, Acute | Details |
| Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | JY43; JY-43 | Phase 1 Clinical | Hangzhou Jiuyuan Gene Biomedical Co Ltd | Multiple Myeloma | Details |
| KYS202002A | KYS-202002A; KYS202002A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| ISB-2001 | ISB-2001; ABBV-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | Details | |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| 211At-OKT10-B10 | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details | |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | Multiple Myeloma | Details |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | Multiple Myeloma | Details | |
| SAR-442085 | SAR-442085 | Phase 1 Clinical | Sanofi | Multiple Myeloma | Details |
| 111Indium labeled daratumumab | City Of Hope National Medical Center, National Cancer Institute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | DARA-PH20 | Approved | Johnson & Johnson Innovative Medicine | Darzalex Faspro, Darzquro, DARZALEX FASPRO, DARZALEX-SC | United States | Multiple Myeloma | Janssen Biotech Inc | 2020-05-01 | Amyloidosis; Anemia, Aplastic; Bone marrow transplant rejection; Hematologic Neoplasms; Hodgkin Disease; Immunoglobulin Light-chain Amyloidosis; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Myelodysplastic Syndromes; Peripheral Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Rejection in heart transplantation; Smoldering Multiple Myeloma | Details |
| Isatuximab | SAR-650984; hu38SB19 | Approved | Immunogen Inc | Sarclisa | United States | Multiple Myeloma | Sanofi-Aventis U.S. Llc | 2020-03-02 | Amyloidosis; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Carcinoma, Non-Small-Cell Lung; Constipation; Diarrhea; Gastrointestinal Hemorrhage; Goiter, Nodular; Hematologic Neoplasms; Hepatomegaly; Hodgkin Disease; Immunoglobulin Light-chain Amyloidosis; Leukemia, Myeloid, Acute; Leukemia, Plasma Cell; Leukemia, T-Cell; Lymphadenopathy; Lymphoma; Lymphoma, Non-Hodgkin; Macroglossia; Multiple Myeloma; Nausea; Neoplasms; Paraproteinemias; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Purpura; Satiety Response; Smoldering Multiple Myeloma | Details |
| Daratumumab | JNJ-54767414 | Approved | Johnson & Johnson Innovative Medicine | Darzalex, 兆珂, 兆珂速 | United States | Multiple Myeloma | Janssen Biotech Inc | 2015-11-16 | Alzheimer Disease; Amyloidosis; Anemia, Aplastic; Autoimmune Diseases; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Genital Neoplasms, Male; Glioblastoma; Glomerulonephritis; Hemangioma, Cavernous, Central Nervous System; Hodgkin Disease; Hypersensitivity; Immunoglobulin Light-chain Amyloidosis; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Primary Effusion; Multiple Myeloma; Myelodysplastic Syndromes; Paraproteinemias; POEMS Syndrome; Prostatic Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency; Skin Diseases; Smoldering Multiple Myeloma; Stevens-Johnson Syndrome; Urologic Neoplasms; Waldenstrom Macroglobulinemia | Details |
Product Reviews
Y***u2023-03-31
0People LikeThis product can be used at < 0.4 ug/ml as a detection agent to quantify anti CD38 antibodies in a binding assay. Anti CD38 antibodies in either bovine serum albumin based sample diluent or murine serum can be detected by this production without a problem. Specific signals from the subsequent streptavidin conjugated enzyme reaction were very strong and very low noise from the negative control antibody group.- Y***u2023-03-16 0People LikeUsed 3 ug/ml of this protein as the capture antigen in an ELISA assay to screen for anti-mouse CD38 mAbs. Very strong signal from the positive control anti-mouse CD38 mAb (clone: NIMR5) and no binding to several anti-human CD38 mAbs or the anti-IgG secondary Ab in the assay. The "ETD of in-stock products: 2 business days" statement on Acro website was accurate. Fast shipment. Professional COA and instructions on how to reconstitute and store this product.
- 1***02019-10-11 0People LikeI bought a lot of products. This protein has high purity and good bioactivity. Whether it is for ELISA or functional assay, all went smoothly. The price is favorable and the service is also good. I support and recommend ACRO! Go ACRO!
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to: